Increasing knowledge of the subject has provided information that prostate cancer is a heterogeneous disease with the coexistence of both AR-responsive and AR-refractory cancer cells responsible for antiandrogen resistance at various degrees. The gene discussed is AR; the disease is prostate carcinoma.